Madeline Carol DePriest
Author pages are created from data sourced from our academic publisher partnerships and public sources.
Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma
- R. Dillman, C. Duma, +4 authors Madeline Carol DePriest
- Journal of immunotherapy
- 1 November 2009
Despite recent advances, median survival for patients with resectable glioblastoma multiforme (GBM) is only 12 to 15 months. We previously observed minimal toxicity and a 9.0-month median survival… Expand